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Abstract - At present, two influenza A viruses, H1N1pdm09 and H3N2, along with influenza B virus co-circulate in the hu-
man population, causing endemic and seasonal epidemic acute febrile respiratory infections, sometimes with life-threat-
ening complications. Detection of influenza viruses in nasopharyngeal swab samples was done by real-time RT-PCR. 
There were 60.2% (53/88) positive samples in 2010/11, 63.4% (52/82) in 2011/12, and 49.9% (184/369) in 2012/13. Among 
the positive patients, influenza A viruses were predominant during the first two seasons, while influenza B type was more 
active during 2012/13. Subtyping of influenza A positive samples revealed the presence of A (H1N1)pdm09 in 2010/11, A 
(H3N2) in 2011/12, while in 2012/13, both subtypes were detected. The highest seroprevalence against influenza A was in 
the age-group 30-64, and against influenza B in adults aged 30-64 and >65. 
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INTRODUCTION
Influenza  viruses  are  classified  into  three  genera 
within the Orthomyxoviridae family: Influenzavirus 
A, Influenzavirus B, and Influenzavirus C. Influenza 
A  and  B  viruses  are  important  human  pathogens 
causing substantial morbidity and mortality world-
wide. They usually cause endemic and epidemic flu, 
self-limited, acute febrile respiratory infection. How-
ever, severe disease and life-threatening complica-
tions such as pneumonia, which is associated with 
increased  rates  of  hospitalization  and  death,  may 
occur in elderly persons, infants, and patients with 
chronic medical conditions (Taubenberger and Mo-
rens, 2008). Influenza C virus sporadically causes a 
mild respiratory illness, has no epidemic potential, 
and does not have severe public health impact.
The genome of influenza A and B viruses con-
sists  of  eight  single-stranded,  negative-sense  RNA 
segments, encoding up to 11 proteins. Influenza A 
viruses are divided into subtypes, based on the an-
tigenic  properties  of  surface  glycoprotein  hemag-
glutinin (H) and neuraminidase (N). There are 16 
different subtypes of H and 9 of N. All known sub-
types, in various combination, circulate in aquatic 
bird and can infect a range of mammal species (pigs, 
horses, cats, seals), but only some of these subtypes 
have  been  identified  in  humans.  Subtypes  H1N1, 
H2N2 and H3N2, were associated with seasonal epi-
demics and three major pandemics of the twentieth 
century (1918, 1957 and 1968, respectively). In the 
spring of 2009, a new influenza A (H1N1)pdm09 vi-
rus emerged and caused the first influenza pandemic 
in more than 40 years. Occasional transmissions of 44 J. RADOVANOV ET AL.
avian H5N1, H7N7 and H9N2 viruses to humans 
have also been recorded (Taubenberger and Morens, 
2010). There are no influenza B virus subtypes. The 
influenza B virus almost exclusively infects humans, 
although it has also been isolated from seals.
Influenza A viruses show rapid genetic evolu-
tion, notably in the gene-coding surface glycopro-
teins (Lavenu et al., 2006; Taubenberger and Morens, 
2010).  Antigenic  drift  is  a  process  of  continuous 
change in the amino acid sequences of the antigenic 
portions of H and N. It results from the accumulation 
of point mutation during viral replication leading to 
new virus strains, causing annual winter outbreaks. 
Antigenic shift is an abrupt, major change in which 
the  virus  acquires  a  new  H  subtype  antigenically 
novel  to  humans,  usually  by  genetic  reassortment 
with another influenza A virus. Most people have no 
immunity to the new subtype, so the virus infects up 
to 50% of the population and quickly spreads, caus-
ing a pandemic (Taubenberger and Morens, 2010). 
Influenza B viruses undergo antigenic drift less rap-
idly than influenza A viruses. They are associated 
with less frequent and less severe epidemics than in-
fluenza A viruses, and they have not caused pandem-
ics (WHO GISN, 2011).
A number of tests can be applied in the diagnosis 
of influenza: conventional viral cell culture, rapid cell 
culture (shell vials), direct or indirect immunofluo-
rescence  assays,  molecular  assays  and  serological 
testing. Serological testing is recommended for ret-
rospective  diagnosis  and  seroepidemiological  sur-
veillance. Molecular tests, such as real-time RT-PCR, 
can be used for fast diagnosis of acute influenza in-
fections, as well as for the detection and investigation 
of outbreaks (WHO GISN, 2011).
MATERIALS AND METHODS
ELISA test
In order to determine the seroprevalence of influen-
za A and B, serum samples from patients suspected 
of having respiratory virus infection, were collected 
from January 2011 to May 2013 in the Center of Vi-
rology of the Institute of Public Health of Vojvodina. 
Specimens were tested for immunoglobulin G anti-
bodies (IgG) against influenza A and B viruses, using 
commercially available enzyme-linked immunosorb-
ent assays (ELISA), (Euroimmune, Lubecq, Germa-
ny). For the presence of IgG antibodies against influ-
enza A and B viruses, a total of 353 and 271 patients 
were assayed in 2011, 398 and 280 in 2012, 333 and 
309 in 2013, respectively. Patient ages ranged from 
younger than 1 year to 83 years.
Testing, calculation and interpretation of results 
were  performed  strictly  following  the  instructions 
of the manufacturer. Samples were tested using an 
automated ELISA system for microtiter plates, Eu-
roimmune  Analyzer  I-2P.  Results  were  evaluated 
semiquantitatively by calculating the ratio of the ex-
tinction value of patient samples over the extinction 
value of the calibrator 2, which was included in the 
test. Results were considered positive if the ratio was 
equal to or greater than 1.1, intermediate if the ratio 
was between 0.8 and 1.1, and negative if the ratio was 
less than 0.8. Positive results for IgG anti-influenza 
antibodies confirmed past infection with this viruses. 
Borderline results were inconclusive and, according 
to the instructions of manufacturer, those samples 
should be retested after 7 days.
Statistical analysis
Differences in the anti-influenza IgG antibody prev-
alence  between  three  seasons  were  calculated  by 
Fisher’s statistical test.
Real-time RT-PCR
Nasopharyngeal swab samples were obtained from 
sentinel  and  hospitalized  patients  with  influenza-
like illness and transferred to the World Health Or-
ganization (WHO) National Influenza Center in the 
Institute of Public Health of Vojvodina in Novi Sad. 
A total of 88, 82, and 369 specimens were collected, 
during the influenza seasons 2010/11, 2011/12, and 
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Samples  were  processed  in  accordance  with 
WHO Global Influenza Surveillance Network rec-
ommended  protocols  (WHO  GISN,  2011).  Viral 
RNA was extracted using a QIAamp Viral RNA Mini 
Kit  (Qiagen,  Germany).  Influenza  detection  and 
subtyping was done by singleplex real-time RT-PCR 
assays  recommended  by  the  WHO  (CDC,  2009). 
Reverse  transcription  and  amplification  were  per-
formed using one-step AgPath-IDTM One-Step RT-
PCR Reagents (Applied Biosystems, USA), and oli-
gonucleotide primer and probe sets designed for de-
tection of universal influenza A, pandemic influenza 
A (H1N1)pdm09, seasonal influenza A (H1N1), A 
(H3N2),  avian  influenza  A  (H5N1)  and  influenza 
B viruses, provided by Centers for Disease Control 
and Prevention (CDC). Negative and positive tem-
Fig 1. Age distribution of anti-influenza A and B IgG positive patients
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plate controls for all primer/probe sets were included 
in each run. The human RNase P gene primer and 
probe set served as an internal positive control for 
human RNA. PCR was performed on Applied Bio-
systems 7500 real-time thermocycler. 
Results were analyzed using Applied Biosystems 
7500  Software  and  the  interpretation  of  data  was 
done according to WHO guidelines (WHO GISN, 
2011). 
RESULTS
Results of serological investigation for influenza A 
and B are summarized in Table 1. The prevalence of 
antibodies against influenza A and B viruses were 
not significantly different in the same year. The pro-
portions of IgG-positive patients for influenza A and 
B in 2011 were 30% (106/353) and 34.3% (93/271), 
in 2012 53.8% (214/398) and 69.3% (194/280), and 
in 2013 77.2% (257/333) and 85.4% (264/309), re-
spectively.  However,  each  year,  seroprevalences  of 
antibodies  to  influenza  A  and  B  viruses  were  ex-
tremely significantly higher than in the previous year 
(P<0.0001). 
Seroprevalences against influenza varied by age 
group (Fig. 1), with adults aged 30-64 having the 
highest seroprevalence for influenza A (43.6%), and 
adults aged 30-64 and >65 for influenza B (48.7% and 
60.8%, respectively). The lowest influenza A age-spe-
cific seroprevalence of 12.5% was in the age-group of 
0-4 years, while the lowest prevalence of influenza B 
antibodies (5.35) was in the age-group 5-14 years. 
Figs. 2 and 3 show the seasonal distribution of 
anti-influenza A- and B IgG-positive patients during 
2011, 2012 and for the first four months of 2013. A 
substantial increase in seroprevalence of both viruses 
was detected at the beginning of 2013. 
The results of real-time RT-PCR testing are sum-
marized in Table 2. Influenza viruses were detected 
by real-time RT-PCR in 60.2% (53/88) of specimens 
taken from patients during 2010/11, 63.4% (52/82) 
in 2011/12 and 49.9% (184/369) in 2012/13. Among 
the  positive  patients,  infections  with  influenza  A 
viruses were much more prevalent than infections 
due to influenza B viruses, throughout the seasons 
2010/11 (84.9% vs. 15.1%) and 2011/12 (96.1% vs 
3.9%). In the 2012/13 season, viruses of type A and 
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type B were about equally distributed among positive 
patients (47.3% vs. 52.7%). 
Subtyping of influenza A-positive samples dur-
ing the first two seasons, revealed the presence of 
only one subtype, A (H1N1)pdm09 in 2010/11, and 
A (H3N2) in 2011/12. In the 2012/13 winter season, 
among the influenza A-positive patients there were 
61  (70.1%)  influenza  (H1N1)pdm09  positive,  22 
(25.3%) influenza A (H3N2) positive, and in 4 (4.6%) 
cases it was not possible to determine the subtype of 
detected influenza A virus. 
Seasonal A (H1N1) and avian (H5N1) subtypes 
were not identified in any sample, during the given 
periods of time.
DISCUSSION
Serological testing is not convenient for early diagno-
sis of acute influenza virus infections, but it may be 
very useful for retrospective diagnosis and seroepi-
demiological surveillance. 
In  this  study,  the  observed  IgG  prevalences 
against influenza A virus varied, depending on the 
year, from 30% to 77.2%, and against influenza B 
virus from 34.3% to 85.4%. However, in the same 
year, prevalences against both viruses were similar. 
Data from a seroepidemiological study conducted 
by Sauerbrei et al. (2009) showed that the preva-
lence  of  IgG  antibodies  against  influenza  A  was 
99,4% and against influenza B 56.7% in a popula-
tion of healthy adult blood-donors in Germany. In 
another investigation, a high number of IgG-pos-
itive for influenza A (93.8%), and a lower number 
of influenza B positive (42.1%), were also observed 
among healthy pregnant women in Germany (Wut-
zler et al., 2009).
After  the  decline  of  maternal  antibodies  dur-
ing the first year of life, the prevalence of antibodies 
Table 1. Results of ELISA testing for IgG anti-influenza A and B antibodies per year
Samples tested in 2011 (%) Samples tested in 2012 (%) Samples tested in 2013 (%)
Influenza A virus
Positive 106 (30) 214 (53.8) 257 (77.2)
Negative 205 (58.1) 137 (34.4) 49 (14.7)
Borderline 42 (11.9) 47 (11.8) 27 (8.1)
Total 353 398 333
Influenza B virus
Positive 93 (34.3) 194 (69.3) 264 (85.4)
Negative 150 (55.4) 83 (29.6) 39 (12.6)
Borderline 28 (10.3) 3 (1.1) 6 (2)
Total 271 280 309
Table 2. Distribution of influenza viruses in patients tested by real-time RT-PCR by season
Positive patients (%)
Season 2010/11 Season 2011/12 Season 2012/13
Influenza A virus 45 (84.9) 50 (96.1) 87 (47.3)
A (H1N1)pdm09 45 (100) - 61 (70.1)
A (H1N1) - - -
A (H3N2) - 50 (100) 22 (25.3)
Unsubtypeable - - 4 (4.6)
Influenza B 8 (15.1) 2 (3.9) 97 (52.7)
Positive/analyzed 53/88 (60.2) 52/82 (63.4) 184/369 (49.9)48 J. RADOVANOV ET AL.
against influenza viruses increases during life time. 
In accordance with this, our serological investigation 
revealed  lower  antibody  prevalences  for  influenza 
A and B in children aged up to 14 years compared 
to adults. Compared to the results of some other in-
vestigations, the prevalences detected in this study 
were generally lower. Sauerbrei et al. (2009) recorded 
very high seroprevalences of influenza A in children 
(82%) by the age of 12 years and in adults (99.4). 
Our results could be explained by the low influenza 
vaccination rate in the population of Vojvodina. It 
is obvious that annual influenza immunization may 
improve protection against influenza virus infections 
during epidemics. 
A substantial increase in the seroprevalence of 
influenza A and B viruses was detected at the end 
of 2012 and beginning of 2013. This was probably a 
consequence of the early beginning of the 2012/13 
winter influenza season, and the high activity of both 
viruses in our Province, as in some other European 
countries (WHO, 2013).
The results of real-time RT-PCR testing show 
that during the first two seasons, influenza A vi-
ruses were predominant, while influenza B viruses 
circulated  at  low  levels.  During  the  2010/11  and 
2011/12 influenza seasons, influenza A types were 
responsible for 84.9% (45/88) and 96.1% (50/82) of 
influenza virus infections, respectively. Only 15.1% 
(8/88)  infections  in  the  first,  and  3.9%  (2/82)  in 
the second season, were due to influenza B type. In 
2010/11, the situation was similar in other Europe-
an countries, as well as in America and most parts 
of Africa and Asia (WHO, 2011), but in 2011/12 
the activity of influenza B type increased in Africa, 
as well as in Eastern and South Asia, and Canada 
(WHO, 2012). During the 2012/13 season, influ-
enza  B  viruses  circulated  in  many  countries  and 
in some of them were the predominant influenza 
viruses (WHO, 2013). Similarly, the activity of in-
fluenza B type also increased in Vojvodina. Infec-
tions with influenza B type were detected in more 
than half (52.7%, 97/184) of positive patients, while 
influenza A infections were confirmed in a slightly 
smaller percentage (47.3%, 87/184).
Historically, influenza pandemics have been as-
sociated with a replacement of the previously circu-
lating influenza A subtype, as in the 1918 pandemic 
virus was A (H1N1). In 1957 it was replaced with 
A (H2N2), which circulated in humans until 1968, 
when it was replaced by A (H3N2). In 1977, influen-
za A (H1N1) was reintroduced, and since then it has 
been co-circulating with A (H3N2) in humans. Influ-
enza A (H1N1)pdm09 virus emerged in spring 2009 
and became the dominant influenza virus around the 
world, causing a pandemic.
One year after the pandemic, during the 2010/11 
influenza season, influenza A (H1N1)pdm09 virus 
was  the  only  detected  influenza  A  subtype  in  the 
Province of Vojvodina. In the same period, this sub-
type was by far the most common influenza virus in 
Europe, while influenza A(H3N2) subtype was rare 
(WHO, 2011). However, in contrast to the pattern 
observed during the 2009 pandemic, in many parts 
of the world, A (H1N1)pdm09 co-circulated with 
other influenza viruses and was no longer the pre-
dominant influenza subtype. For example, in North 
America, influenza A (H1N1)pdm09 co-circulated 
with influenza A (H3N2) and influenza B viruses. 
Data from this study show that in 2011/12, the 
only detected influenza A subtype was A (H3N2). 
During that season, the predominant virus varied 
widely in different European countries, but overall 
influenza  A  (H3N2)  was  the  most  commonly  re-
ported (WHO, 2012). The situation was similar for 
Central Asia, South America and Africa. In North 
America, the distribution of influenza A subtypes 
varied,  so  Mexico  reported  almost  exclusively  in-
fluenza A (H1N1)pdm09, while in the USA, influ-
enza A (H3N2) was the most active influenza virus 
(WHO, 2012).
The dominant influenza A virus subtype during 
the season 2012/13 was A (H1N1)pdm09, which was 
detected  in  70.1%  (61/87)  of  influenza  A-positive 
samples. The presence of influenza A (H3N2) sub-
type was revealed in 25.3% (22/87) of positive sam-
ples. A similar distribution of influenza A subtypes 
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Asia, Central and South America, while in others, 
and in most parts of North America, influenza A 
(H3N2) was predominant (WHO, 2013). Out of 87 
influenza A-positive samples, 4 (4.6%) could not be 
subtyped. These samples were sent to WHO Collab-
orating Centers for Research on Influenza (CCRI) in 
London, as per WHO recommendation that all un-
subtypeable influenza A specimens should be imme-
diately sent for further characterization to one of the 
six WHO CCRI. Influenza viruses constantly change 
their surface glycoproteins that are responsible for 
receptor binding and antigenic properties of a virus. 
This process can result in the emergence of a virus 
with different host-range, tissue tropism, virulence, 
or antiviral drug resistance. This is why the charac-
terization of all unsubtypeable, potentially novel, in-
fluenza viruses is of great importance. 
Seasonal influenza A (H1N1) subtype was not 
detected in this study. Reduction in seasonal in-
fluenza A (H1N1) activity was the most obvious 
effect of the 2009 pandemic, while seasonal influ-
enza A (H3N2) continued to circulate. At present, it 
seems that emerging pandemic influenza A (H1N1)
pdm09 virus has replaced the previously circulat-
ing seasonal A (H1N1). It is not fully understood 
why  pandemic  influenza  viruses  replace  existing 
seasonal influenza A subtypes and strains. Results 
from some studies show that heterosubtypic immu-
nity – short-lived immunity which is cross-protec-
tive against different influenza A subtypes – is able 
to inhibit reinfection by any new strain in animal 
models (Grebe et al., 2008). It is possible that dur-
ing pandemics, a substantial fraction of the global 
population is infected with the new virus and is 
then transiently immune to infection with the pre-
viously circulating subtypes. This leaves a critically 
low number of susceptible individuals, leading to 
the extinction of seasonal influenza strains (Blyth 
et al., 2010).
Although avian influenza A (H5N1) subtype was 
not detected in this study, continued monitoring of 
the occurrence of human infection with this virus is 
critically important to assess its pandemic potential. 
The case fatality rate associated with human infec-
tions with the highly pathogenic H5N1 avian sub-
type can reach nearly 60%, causing great concern 
that  adaptation  of  this  virus  to  human-to-human 
transmission  could  cause  a  devastating  pandemic 
(Taubenberger and Morens, 2008).
Endemic  and  epidemic  influenza  virus  infec-
tions  continue  to  be  a  major  health  threat.  The 
rapid, continuous and unpredictable nature of in-
fluenza viral evolution makes vaccine strategies and 
pandemic planning difficult. The recent emergence 
of the swine-origin influenza A (H1N1)pdm09 sub-
type and the ongoing highly pathogenic avian influ-
enza A (H5N1) epizootic, associated with a grow-
ing number of human “spill-over” infections, has 
heightened the importance of rapid and accurate 
identification and subtyping of influenza viruses for 
surveillance, outbreak management, diagnosis and 
treatment. 
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